Endocarditis caused by methicillin-susceptible Staphylococcus aureus with reduced susceptibility to vancomycin: A case report

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Perazzi, Beatriz ^a   Bello, Natalia ^a   Mollerach, Marta ^a   Vay, Carlos ^a   Lasala, María Beatriz ^a   Famiglietti, Angela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALOTIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARGENTINA; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; BLOOD CULTURE; CASE REPORT; CELLULITIS; DRUG ERUPTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBOLISM; EOSINOPHILIA; HUMAN; HUMAN TISSUE; HYPOTROPHY; ILIOPSOAS MUSCLE; INTERSTITIAL NEPHRITIS; LUMBOSACRAL SPINE; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SYSTOLIC HEART MURMUR; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 79959970431     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-292     Document Type: Article

References (24)

1. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. K Hiramatsu N Aritaka H Hanaki S Kawasaki Y Hosoda S Hori Y Fukuchi I Kobayashi, Lancet 1997 350 1670 1673 10.1016/S0140-6736(97)07324-8 9400512 (Pubitemid 28036828)
2. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. M Wootton RA Howe R Hillman TR Walsh PM Bennett AP MacGowan, J Antimicrob Chemother 2001 47 399 403 10.1093/jac/47.4.399 11266410 (Pubitemid 32303403)
3. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. FY Chang J Peacock M Musher P Triplett B MacDonald JM Mylotte A O'Donnell MM Wagener VL Yu, Medicine 2003 82 333 339 10.1097/01.md.0000091184.93122.09 14530782 (Pubitemid 37229468)
4. Vancomycin therapeutic guidelines A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists. MJ Rybak BM Lomaestro JC Rotschefer RC Moellering WA Craig M Billeter JR Dalovisio DP Levine, Clin Infect Dis 2009 49 325 327 10.1086/600877 19569969
5. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. DP Levine BS Fromm BR Reddy, Ann Intern Med 1991 115 739 741 1929043
6. Initial low-dose gentamicin for Staphylococcus aureus and endocarditis is nephrotoxic. SA Cosgrove GA Vigliani M Campion E Abrutyn GR Corey DP Levine ME Rupp HF Chambers AW Karchmer HW Boucher, Clin Infect Dis 2009 48 713 721 10.1086/597031 19207079
7. Epidemiological and microbiological characterisation of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. SK Fridkin J Hageman LK McDougal J Mohammed WR Jarvis TM Perl FC Tenover, Clin Infect Dis 2003 36 429 439 10.1086/346207 12567300 (Pubitemid 36241308)
8. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. K Hiramatsu H Hanaki T Ino K Yabuta T Oguri FC Tenover, J Antimicrob Chemother 1997 40 135 136 10.1093/jac/40.1.135 9249217 (Pubitemid 27341646)
9. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. MC Ploy C Grelaud C Martin L de Lumley F Denis, Lancet 1998 351 1212 9643728 (Pubitemid 28171844)
10. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. J Ariza M Pujol J Cabo C Pena N Fernandez J Linares J Avats F Gudiol, Lancet 1999 353 1587 1588 10.1016/S0140-6736(99)01017-X 10334262 (Pubitemid 29219213)
11. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. R Geisel FJ Schmitz L Thomas G Berns O Zetsche B Ulrich AC Fluit H Labischinsky W White, J Antimicrob Chemother 1999 43 846 848 10.1093/jac/43.6.846 10404328 (Pubitemid 29273739)
12. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. ME Reverdy S Jarraud S Bobin-Dubreux E Burel P Girardo G Lina F Vandenesch J Etienne, Clin Microbiol Infect 2001 7 267 272 10.1046/j.1198-743x.2001.00256.x 11422254 (Pubitemid 34960307)
13. First report of methicillin resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. S Trakulsomboon S Danchaivijitr Y Rongrungruang C Dhiraputra W Susaemgrat T Ito K Hiramatsu, J Clin Microbiol 2001 39 591 595 10.1128/JCM.39.2.591-595.2001 11158112 (Pubitemid 32150823)
14. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. A Yusof A Engelhardt A Karlsson L Bylund P Vidh K Mills M Wootton TR Walsh, J Clin Microbiol 2008 46 3042 3047 10.1128/JCM.00265-08 18596146
15. Vancomycin MIC plus heteroresistance and outcome methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. AC Musta K Riederer S Shemes P Chase J Jose LB Johnson R Khatib, J Clin Microbiol 2009 47 1640 1644 10.1128/JCM.02135-08 19369444
16. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. I-J Bae JJ Federspiel JM Mirá CW Woods L Park MJ Rybak TH Rude S Bradley S Bukovski C García de la María SS Kanj TM Korman F Marco DR Murdoch P Plesiat M Rodriguez-Creixems P Reinbott L Steed P Tattevin M-F Tripodi KL Newton R Corey VG Foeler Jr for the International Collaboration on endocarditis-microbiology investigator, J Infect Dis 2009 200 1355 1366 10.1086/606027 19811099
17. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. Y Maor M Hagin N Belausov N Keller D Ben-David G Rahav, J Infect Dis 2009 199 619 624 10.1086/596629 19199552
18. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylocococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. MR Moore F Perdreau-Remington HF Chambers, Antimicrob Agents Chemother 2003 47 1262 1266 10.1128/AAC.47.4.1262- 1266.2003 12654656 (Pubitemid 36368583)
19. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. S Bobin-Dubreux ME Reverdy C Nervi M Rougier A Bolmström F Vandenesch J Etienne, Antimicrob Agents Chemother 2001 45 349 352 10.1128/AAC.45.1.349-352.2001 11120996 (Pubitemid 32039145)
20. Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus. DN Fusco EL Alexander SA Weisenberg JR Mediavilla BN Kreisswirth AN Schuetz SG Jenkins KY Rhee, Diagn Microbiol Infect Dis 2009 65 180 183 10.1016/j.diagmicrobio.2009.05. 017 19748429
21. Development of reduced vancomycin susceptibility in methicillin- susceptible Staphylococcus aureus. SK Pillai C Wennersten L Venkataraman GM Eliopoulos AW Karchmer, Clin Infect Dis 2009 49 1169 1174 10.1086/605636 19769538
22. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. ME Ruiz IC Guerrero CU Tuazon, Clin Infect Dis 2002 35 1018 1020 10.1086/342698 12355391 (Pubitemid 35178321)
23. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. MH Murthy ME Olson RW Wickert PD Fey Z Jalali, J Med Microbiol 2008 57 1036 1038 10.1099/jmm.0.2008/000588-0 18628509
24. Clinical experience with daptomycin bateremia and endocarditis. DP Levine, J Antimicrob Chemother 2008 62 suppl3 35 39 18408238